SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-24-007407
Filing Date
2024-02-28
Accepted
2024-02-28 08:49:00
Documents
113
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mrsn-20231231.htm   iXBRL 10-K 2190735
2 EX-10.24 exhibit1024-mbalaofferlett.htm EX-10.24 38745
3 EX-10.43 exhibit1043-mersanaxamende.htm EX-10.43 45887
4 EX-23.1 exhibit231-eyconsent.htm EX-23.1 8199
5 EX-31.1 exhibit31110kfy2023q4.htm EX-31.1 10069
6 EX-31.2 exhibit31210kfy2023q4.htm EX-31.2 10119
7 EX-32.1 exhibit32110kfy2023q4.htm EX-32.1 6213
8 EX-97 exhibit97-mersanaxamendeda.htm EX-97 23441
14 logo1.jpg GRAPHIC 6390
15 mrsn-20231231_g1.jpg GRAPHIC 57050
16 mrsn-20231231_g2.jpg GRAPHIC 35615
17 mrsn-20231231_g3.jpg GRAPHIC 26325
18 mrsn-20231231_g4.jpg GRAPHIC 24748
19 mrsn-20231231_g5.jpg GRAPHIC 25233
20 mrsn-20231231_g6.jpg GRAPHIC 45970
21 mrsn-20231231_g7.jpg GRAPHIC 35285
  Complete submission text file 0001628280-24-007407.txt   10294625

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20231231.xsd EX-101.SCH 62399
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20231231_cal.xml EX-101.CAL 83165
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20231231_def.xml EX-101.DEF 274130
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20231231_lab.xml EX-101.LAB 845339
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20231231_pre.xml EX-101.PRE 551532
114 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20231231_htm.xml XML 1227355
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38129 | Film No.: 24690468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)